

Cardiovascular disease: risk assessment and reduction, including lipid modification

**Supplement: National Guideline Centre
acknowledgements**

NICE guideline NG238

NGC technical team list

December 2023

Final

Developed by NICE

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2023. All rights reserved. Subject to Notice of Rights.

ISBN

[add for final publication version only, delete this text for consultation version]

Contents

1	NICE Guideline Development Team NGC technical team	6
1.1	Acknowledgements	7

Dr Mark Glover was a member of the committee for the March 2022 update of the Hypertension guideline (NG136), the May 2023 update of the CVD prevention risk tools, dietary cholesterol and statins (CG181) and the escalation of therapy for secondary prevention update of CG181 until his very sad and untimely death in February 2023. The Chair and other members of the committee pay tribute to Mark's work on the CVD suite of guideline updates and remember him as a valued colleague and friend.

1 NICE Guideline Development Team NGC technical team

Name	Role
Serena Carville	Associate Director/Guideline Lead (until May 2023)
Lina Gulhane	Head of Information Specialists, GDT NGC
Kusal Lokuge	Technical Analyst (Economics) (from July 2023)
Alfredo Mariani	Technical Analyst (Economics)
Eleanor Samarasekera	Lead Technical Analyst
Sharon Swain	Associate Director/Guideline Lead (from May 2023)
Amelia Unsworth	Senior Project Manager
Melina Vasileiou	Technical Analyst (until July 2023)
David Wonderling	Head of Health Economics

NICE other technical staff

Name	Role
Lindsay Claxton	Technical Adviser (Economics)
Jasdeep Hayre	Associate Director
Vanessa Kam	Analyst
Lynne Kincaid	Senior Analyst
Alan Moore	HTA Analyst
Patrick Muller	Technical Adviser
Shaun Rowark	Scientific Adviser
Miaoqing Yang	Senior Technical Analyst (Economics)

NICE Technical Support Unit

University of Bristol

Name	Role
Beatrice Downing	Senior Research Associate
Nicky Welton	

CPRD, MHRA

Name	Role
Michael Lonergan	
Jessie Oyinlola	
Ellie Yelland	
Rachael Williams	

University of Oxford

Name	Role
Boby Mihaylova	
Junwen Zhou	

1.1 Acknowledgements

The development of this guideline was greatly assisted by the following people:

- Stephen Deed
- Amber Hernaman
- Clare Jones
- Kate Lovibond
- Joseph Runicles
- Toby Sands